#ASH24: J&J’s Darzalex hits primary endpoint in Phase 3 early-stage multiple myeloma trialnews2024-11-05T17:14:17+00:00November 5th, 2024|Endpoints News|
#ASH24: Gilead and Arcellx spotlight safety of multiple myeloma cell therapy, dose first patient in Phase 3news2024-11-05T16:08:48+00:00November 5th, 2024|Endpoints News|
#ASH24: Sanofi reveals positive Phase 3 data for BTK inhibitor from $3.7B Principia takeovernews2024-11-05T15:57:22+00:00November 5th, 2024|Endpoints News|
Syndax inks a $350M royalty deal; FDA pushes back decision on Organon’s eczema drugnews2024-11-05T15:28:35+00:00November 5th, 2024|Endpoints News|
#ASH24: Beam discloses first clinical data on base-edited sickle cell therapy, one patient deathnews2024-11-05T15:19:56+00:00November 5th, 2024|Endpoints News|
PrognomiQ raises $34M for lung cancer testnews2024-11-05T14:00:45+00:00November 5th, 2024|Endpoints News|
Vertex makes money from sickle cell therapy Casgevynews2024-11-05T12:20:41+00:00November 5th, 2024|Endpoints News|
Nektar divests manufacturing site and reagent arm for $90M news2024-11-05T12:03:51+00:00November 5th, 2024|Endpoints News|
Ferrum Health CEO: Why AI for medical care adoption has been slownews2024-11-05T12:00:58+00:00November 5th, 2024|Endpoints News|
Sana narrows focus again to zero in on diabetes and autoimmune diseasenews2024-11-05T11:42:44+00:00November 5th, 2024|Endpoints News|
